Local
Researchers develop medication combating opioid crisis
A Roundtable is a way to meet new people and discuss this article in person at a local coffee shop or other venue.
Roundtables are designed for groups of four, with a shared subject and room for everyone to speak. Come for discussion, with no dating expectation.
Source: The Paisano

A research team at UT Health San Antonio has spearheaded the development of a groundbreaking medication designed to reverse opioid overdoses and prevent relapses. Methocinnamox, or MCAM, has begun its initial stage of human clinical trials. Currently, the existing medication to reverse an opioid overdose is naloxone. Similar to naloxone, MCAM is an opioid receptor antagonist. MCAM works by binding to opioid receptors, which removes and blocks opioids from attaching to said receptors. Unlike naloxone, MCAM’s effects last a longer amount of time. A single dose of naloxone lasts for 30 minutes, while an MCAM dose can hold out for several weeks. MCAM also represses the euphoric and addictive effects of opioids for the same time period. For those with Opioid Use Disorder, this diminishes the potential for abuse, preventing relapse. The Paisano spoke with Charles France, Ph.D., a Robert A.
This excerpt comes from the named source. Read the original for the full reporting.
Read the original at The Paisano



